Autoimmune myasthenia gravis after COVID-19 in a triple vaccinated patient

##plugins.themes.bootstrap3.article.main##

##plugins.themes.bootstrap3.article.sidebar##

Published Sep 24, 2022
DOI: https://doi.org/10.22551/2022.36.0903.10212
Cristina-Georgiana Croitoru Dan Iulian Cuciureanu Iulian Prutianu Petru Cianga

Abstract

Despite a well characterized mechanism, Myasthenia gravis (MG) remains a dilemma in terms of etiology. Several case reports and series of cases suggest a potential cause-effect relation between SARS-CoV-2 infection or vaccination and MG. We present the case of an autoimmune MG occurring post Covid-19 in an elderly male, vaccinated with three doses of the BNT162b2/Pfizer-BioNTech vaccine. The 78-year-old male was admitted in the Neurology Clinic in early November 2021 with double vision, bilateral ptosis, dysphonia and dysphagia, 16 days after receiving a third dose of the BNT162b2/Pfizer-BioNTech SARS-CoV-2 vaccine and 12 days after testing positive for SARS-CoV-2 infection. The symptoms began to emerge at 9 days after COVID-19 diagnosis. Clinical neurological examination included ice-pack test and intramuscular neostigmine, both with positive results. Myasthenia gravis positive diagnosis was confirmed by slow repetitive nerve stimulation and abnormally increased serum levels of antibodies against acetylcholine receptors. Due to patients refusal of further hospitalization, he was discharged with therapy recommendations. Under treatment with oral pyridostigmine, but no oral corticosteroid due to therapeutic noncompliance, the patient was readmitted two months later with aggravated symptoms. The myasthenic crisis was successfully treated with intravenous immunoglobulins, corticosteroid therapy and oral pyridostigmine. The novelty of the current case resides in the fact that, to the best of our knowledge, appears to be the first case of MG clinically manifested after COVID-19 infection in a fully vaccinated patient.

##plugins.themes.bootstrap3.article.details##

Keywords

post-infectious autoimmune myasthenia gravis, COVID-19, SARS-CoV-2 vaccination, cause-effect relationship

References
1. Bchtenia M, Girard C, Duchaine C, Laprise C. The outbreak of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): A review of the current global status. J Infect Public Health. 2020; 13(11):1601-1610. doi: 10.1016/j.jiph.2020.07.011
2. Guidon AC, Amato AA. COVID-19 and neuromuscular disorders. Neurology. 2020; 94(22):959-969. doi: 10.1212/WNL.0000000000009566
3. Gutierrez-Ortiz C, Mendez-Guerrero A, Rodrigo-Rey S, et al. Miller-Fischer Syndrome and polyneuritis cranialis in COVID-19. Neurology. 2020; 95:e601-605. doi:10.1212/WNL.0000000000009619
4. Taheri A, Davoodi L, Soleymani E, Ahmadi N. New-onset myasthenia gravis after novel coronavirus 2019 infection. Respirol Case Rep. 2022; 10(6):e0978. doi: 10.1002/rcr2.978
5. Ghafouri-Fard S, Azimi T, Hussen BM, Taheri M, Jalili Khoshnoud R. A Review on the Role of Non-Coding RNAs in the Pathogenesis of Myasthenia Gravis. Int J Mol Sci. 2021; 22(23):12964. doi: 10.3390/ijms222312964
6. Kawasaki T, Kawai T. Toll-like receptor signaling pathways. Front Immunol. 2014; 5:461. doi: 10.3389/fimmu.2014.00461
7. Cusick MF, Libbey JE, Fujinami RS. Molecular mimicry as a mechanism of autoimmune disease. Clin Rev Allergy Immunol. 2012; 42(1):102-111. doi:10.1007/s12016-011-8294-7
8. Cavalcante P, Cufi P, Mantegazza R, Berrih-Aknin S, Bernasconi P, Le Panse R. Etiology of myasthenia gravis: innate immunity signature in pathological thymus. Autoimmun Rev. 2013; 12(9):863-74. doi: 10.1016/j.autrev.2013.03.010
9. Jaretzki A 3rd, Barohn RJ, Ernstoff RM, et al. Mysthenia gravis: recomendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology. 2000; 55(1):16-23. doi: 10.1212/wnl.55.1.16
10. Watad A, De Marco G, Mahajna H, et al. Immune-Mediated Disease Flares or New-Onset Disease in 27 Subjects following mRNA/DNA SARS-CoV-2 Vaccination. Vaccines (BAsel). 2021; 9(5):435. doi: 10.3390/vaccines9050435
11. Chavez A, Pougnier C. A Case of COVID-19 Vaccine Associated New Diagnosis Myasthenia Gravis. J Prim Care Community Health. 2021; 12:21501327211051933. doi: 10.1177/21501327211051933
12. Lee MA, Lee C, Park JH, Lee JH. Early-Onset Myasthenia Gravis Following COVID-19 Vaccination. J Korean Med Sci. 2022; 37(10):e50. doi: 10.3346/jkms.2022.37.e50
13. Pérez Álvarez ÁI, Suárez Cuervo C, Fernández Menéndez S. SARS-CoV-2 infection associated with diplopia and anti-acetylcholine receptor antibodies. Neurologia (Engl Ed). 2020; 35(4):264-65. doi: 10.1016/j.nrl.2020.04.003
14. Restivo DA, Centonze D, Alesina A, Marchese-Ragona R. Myasthenia Gravis Associated With SARS-CoV-2 Infection. Ann Intern Med. 2020; 173(12):1027-28. doi:10.7326/L20-0845
15. Huber M, Rogozinski S, Puppe W, et al. Postinfectious Onset of Myasthenia Gravis in a COVID-19 Patient. Front Neurol. 2020 11:576153. doi: 10.3389/fneur.2020.576153
16. Sriwastava S, Tandon M, Kataria S, Daimee M, Sultan S. New onset of ocular myasthenia gravis in a patient with COVID-19: a novel case report and literature review. J Neurol. 2021; 268(8):2690-96. doi: 10.1007/s00415-020-10263-1
17. Muhammed L, Baheerathan A, Cao M, Leite MI, Viegas S. MuSK Antibody-Associated Myasthenia Gravis With SARS-CoV-2 Infection: A Case Report. Ann Intern Med. 2021; 174(6):872-73. doi: 10.7326/L20-1298
18. Bhandarwar A, Jadhav S, Tandur A, Dhimole N, Wagh A, Bhondve S. Management of thymomatous myasthenia gravis - Case report of a rare Covid19 infection sequelae. Int J Surg Case Rep. 2021; 81:105771. doi: 10.1016/j.ijscr.2021.105771
19. Muralidhar Reddy Y, Osman S, Murthy JMK. Temporal association between SARS-CoV-2 infection and new-onset myasthenia gravis: is it causal or coincidental? BMJ Case Rep. 2021; 14(7):e244146. doi: 10.1136/bcr-2021-244146
20. Karimi N, Okhovat AA, Ziaadini B, Haghi Ashtiani B, Nafissi S, Fatehi F. Myasthenia gravis associated with novel coronavirus 2019 infection: A report of three cases. Clin Neurol Neurosurg. 2021; 208:106834. doi: 10.1016/j.clineuro.2021.106834
21. Assini A, Gandoglia I, Damato V, Rikani K, Evoli A, Del Sette M. Myasthenia gravis associated with anti-MuSK antibodies developed after SARS-CoV-2 infection. Eur J Neurol. 2021; 28(10):3537-39. doi: 10.1111/ene.14721
22. Galassi G. Marchioni A. Myasthenia gravis at the crossroad of COVID-19: focus on immunological and respiratory interplay. Acta Neurol Belg. 2021; 121(3):633-642. doi: 10.1007/s13760-021-01612-6
How to Cite
Croitoru, C.-G., Cuciureanu, D. I., Prutianu, I., & Cianga, P. (2022). Autoimmune myasthenia gravis after COVID-19 in a triple vaccinated patient. Archive of Clinical Cases, 9(3), Arch Clin Cases. 2022; 9(3):104-107. https://doi.org/10.22551/2022.36.0903.10212
Issue
Vol. 9 No. 3 (2022)
Section
Case Reports

Archive of Clinical Cases is protected by copyright and may be used in accordance with copyright and other applicable laws. Content available at www.clinicalcases.eu and our digital applications is intended for personal noncommercial use.

Authors who submit a manuscript for publication in Archive of Clinical Cases agree to the following terms: a. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. b. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. c. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) only after the final version of the manuscript was accepted and published, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access). d. It is compulsory that before submission authors ensure that their work was not published in any other medical journals or pending acceptance for publication and that "Archives of Clinical Cases" is the only beneficiary at that moment if their work/case will be accepted by us.

Guidelines for linking to www.clinicalcases.eu a. The main purpose of the site linking to the Archive of Clinical Casess site should be educational. b. Links should be made to the Archive of Clinical Casess home page (www.clinicalcases.eu) or to the articles abstract. c. It is forbidden to use the Archive of Clinical Casess cover by outside organizations unless permission has been granted in advance, notifying our Secretary. d. Material owned by the Archive of Clinical Cases (including the name, logo, cover, and text) may not be used in any manner that may induce the idea or suggest that the Archive of Clinical Cases is in some way recommending a specific company, product or service. e. You must not use or allow others to access or use, all or any part of our Site or the contents and/or applications on it for commercial purposes without our permission. To seek permission to do anything prohibited by or not contained in these TERMS, or which requires our prior consent or agreement, you can contact us.

How to Cite

Croitoru, C.-G., Cuciureanu, D. I., Prutianu, I., & Cianga, P. (2022). Autoimmune myasthenia gravis after COVID-19 in a triple vaccinated patient. Archive of Clinical Cases, 9(3), Arch Clin Cases. 2022; 9(3):104-107. https://doi.org/10.22551/2022.36.0903.10212